Current applications of multiparameter flow cytometry in plasma cell disorders

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801RYG" target="_blank" >RIV/61988987:17110/17:A1801RYG - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/17:E0106608 RIV/65269705:_____/17:00068637

Výsledek na webu

<a href="http://dx.doi.org/10.1038/bcj.2017.90" target="_blank" >http://dx.doi.org/10.1038/bcj.2017.90</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/bcj.2017.90" target="_blank" >10.1038/bcj.2017.90</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Current applications of multiparameter flow cytometry in plasma cell disorders

Popis výsledku v původním jazyce

Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic workup because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenstrom macroglobulinemia.

Název v anglickém jazyce

Current applications of multiparameter flow cytometry in plasma cell disorders

Popis výsledku anglicky

Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic workup because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenstrom macroglobulinemia.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV17-30089A" target="_blank" >NV17-30089A: Detailní genomická analýza zbytkových klonů mnohočetného myelomu: přístup pro individualizaci cílené terapie</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BLOOD CANCER JOURNAL

ISSN

2044-5385

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

10/2017

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

000413469800001

EID výsledku v databázi Scopus

—